These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10442358)

  • 41. The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer.
    Blijham GH
    J Infus Chemother; 1996; 6(3):114-7. PubMed ID: 9229320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
    Grem JL
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
    Loeffler TM; Hausamen TU
    J Infus Chemother; 1996; 6(3):137-40. PubMed ID: 9229325
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer.
    Fujii M
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):55-60. PubMed ID: 10442363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
    Ciccolini J; Gross E; Dahan L; Lacarelle B; Mercier C
    Clin Colorectal Cancer; 2010 Oct; 9(4):224-8. PubMed ID: 20920994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study.
    Feng JP; Yuan XL; Li M; Fang J; Xie T; Zhou Y; Zhu YM; Luo M; Lin M; Ye DW
    Colorectal Dis; 2013 Jan; 15(1):27-33. PubMed ID: 22594556
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer.
    Acharya G; Cruz Carreras MT; Rice TW
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29167217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vive la difference: sex and fluorouracil toxicity.
    Macdonald JS
    J Clin Oncol; 2002 Mar; 20(6):1439-41. PubMed ID: 11896088
    [No Abstract]   [Full Text] [Related]  

  • 50. The association between systemic immune-inflammation index and cardiotoxicity related to 5-Fluorouracil in colorectal cancer.
    Liu X; Wang Y; Wang W; Dong H; Wang G; Chen W; Chen J; Chen W
    BMC Cancer; 2024 Jun; 24(1):782. PubMed ID: 38951749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Importance of methanogenic flora in intestinal toxicity during 5-fluorouracil therapy for colon cancer.
    Rana SV
    J Clin Gastroenterol; 2013 Jan; 47(1):9-11. PubMed ID: 23222210
    [No Abstract]   [Full Text] [Related]  

  • 52. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
    Cwikiel M; Albertsson M; Kinhult S; Eskilsson J
    Cancer; 2000 Aug; 89(3):711-2. PubMed ID: 10931477
    [No Abstract]   [Full Text] [Related]  

  • 53. 5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker.
    Alessandrino F; Qin L; Cruz G; Sahu S; Rosenthal MH; Meyerhardt JA; Shinagare AB
    Abdom Radiol (NY); 2019 Sep; 44(9):3099-3106. PubMed ID: 31250179
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Have enteric infections a role in 5-fluorouracil-associated diarrhea?
    Cascinu S; Catalano G
    Support Care Cancer; 1995 Sep; 3(5):322-3. PubMed ID: 8520881
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes research in the health-care system: driven by results.
    Shermock KM
    Value Health; 2002; 5(1):3-4. PubMed ID: 11873381
    [No Abstract]   [Full Text] [Related]  

  • 56. The cost of 5-FU.
    Ryan RF
    Plast Reconstr Surg; 2001 May; 107(6):1613. PubMed ID: 11347563
    [No Abstract]   [Full Text] [Related]  

  • 57. Skin reaction to systemic 5-FU -- a therapeutic bonus.
    Omura EF
    N Engl J Med; 1977 Oct; 297(17):946. PubMed ID: 904673
    [No Abstract]   [Full Text] [Related]  

  • 58. Studies on the allergenicity of 5-fluorouracil.
    Leyden JJ; Kligman AM
    J Dermatol Surg Oncol; 1977; 3(5):518-9. PubMed ID: 925250
    [No Abstract]   [Full Text] [Related]  

  • 59. Indirect drug-related costs.
    Moore N; Briffaut C; Noblet C; Normand CA; Thuillez C
    Lancet; 1995 Mar; 345(8949):588-9. PubMed ID: 7776802
    [No Abstract]   [Full Text] [Related]  

  • 60. Admissions to hospital due to drugs.
    Parkinson T; Knight AH
    Br Med J; 1969 Mar; 1(5647):843. PubMed ID: 5773790
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.